Schwarcz, Szandra
Kovács, Patrik
Kovács, Tünde
Ujlaki, Gyula
Nyerges, Petra
Uray, Karen
Bai, Péter
Mikó, Edit http://orcid.org/0000-0001-7584-445X
Funding for this research was provided by:
NKFIH (K124141, TKP2021-EGA-19, TKP2021-EGA-20, FK128387)
Hungarian Academy of Sciences (POST-COVID2021-33)
Bolyai fellowship
New National Excellence Program of the Ministry of Human Capacities (ÚNKP-20-3-I-DE-301, ÚNKP-21-3-I-DE-105, ÚNKP-22-3-II-DE-230)
University of Debrecen
Article History
Received: 9 December 2022
Accepted: 12 April 2023
First Online: 5 May 2023
Declarations
:
: Péter Bai is a CEO and shareholder of Holobiont Diagnostics LTD, a developer of cancer diagnostic tests. Other authors declare no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.